As of 2024-12-12, the EV/EBITDA ratio of Flexion Therapeutics Inc (FLXN) is -7.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLXN's latest enterprise value is 564.21 mil USD. FLXN's TTM EBITDA according to its financial statements is -78.25 mil USD. Dividing these 2 quantities gives us the above FLXN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.7x - 16.9x | 15.0x |
| Forward P/E multiples | 15.8x - 22.8x | 18.5x |
| Fair Price | (27.27) - (29.10) | (28.79) |
| Upside | -399.0% - -419.1% | -415.7% |
| Date | EV/EBITDA |